Mirati Therapeutics, Inc. (MRTX)

NASDAQ: MRTX · IEX Real-Time Price · USD
91.98
-4.28 (-4.44%)
Dec 5, 2022 3:15 PM EST - Market open
-4.44%
Market Cap 5.27B
Revenue (ttm) 11.80M
Net Income (ttm) -738.01M
Shares Out 56.22M
EPS (ttm) -11.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 815,083
Open 96.21
Previous Close 96.25
Day's Range 88.69 - 96.47
52-Week Range 32.96 - 154.17
Beta 0.83
Analysts Buy
Price Target 118.00 (+28.3%)
Earnings Date Nov 8, 2022

About MRTX

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclini... [Read more]

Industry Biotechnology
IPO Date Jun 29, 2004
CEO Charles Baum
Employees 413
Stock Exchange NASDAQ
Ticker Symbol MRTX
Full Company Profile

Financial Performance

In 2021, MRTX's revenue was $72.09 million, an increase of 438.08% compared to the previous year's $13.40 million. Losses were -$581.78 million, 62.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for MRTX stock is "Buy." The 12-month stock price forecast is 118, which is an increase of 28.33% from the latest price.

Price Target
$118
(28.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Checkpoint Inhibitor T...

3 days ago - PRNewsWire

Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO

SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced a late-breaking presentation of concurrent combination resu...

1 week ago - PRNewsWire

Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decisio...

1 week ago - Zacks Investment Research

Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle

Big Pharma suitors could be looking to buy Mirati Therapeutics, according to reports that sent MRTX stock close to a breakout Wednesday. The post Mirati Therapeutics Surges As Big Pharma Reportedly Prep...

1 week ago - Investors Business Daily

MRTX Stock Alert: What to Know as Mirati Therapeutics Considers Potential Takeover

Mirati Therapeutics (NASDAQ: MRTX ) stock is a hot topic on Wednesday as the cancer drugmaker considers a potential takeover. According to insider sources, several large pharmaceutical companies are sho...

1 week ago - InvestorPlace

Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat

Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark.

3 weeks ago - Zacks Investment Research

Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of 10.69% and 15.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent co...

3 weeks ago - PRNewsWire

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update...

Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation SAN DIEGO , Nov. 8, 2022 /PRNewswire/ --...

3 weeks ago - PRNewsWire

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO , Nov. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 13 new employees ...

1 month ago - PRNewsWire

Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Mirati Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Updates

SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2022 along with r...

1 month ago - PRNewsWire

Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patien...

SAN DIEGO and LOS ANGELES , Oct. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial sta...

Other symbols: AADI
1 month ago - PRNewsWire

4 Biotech Stocks With Huge Incoming Catalysts

All four of these drugmakers are expecting important FDA approval decisions over the next few months.

Other symbols: BIIBGILD
1 month ago - The Motley Fool

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences

SAN DIEGO , Sept. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.

2 months ago - PRNewsWire

3 Stocks Expecting Good News From the FDA

Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.

Other symbols: HRTXNVAX
2 months ago - The Motley Fool

Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth

Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.

Other symbols: AMGN
2 months ago - Investors Business Daily

Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer

Adagrasib demonstrates promising clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients with advanced colorectal cancer (CRC) harb...

2 months ago - PRNewsWire

Mirati (MRTX) Up 5.3% Since Last Earnings Report: Can It Continue?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat

Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.

4 months ago - Zacks Investment Research

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of 9.92% and 143.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2022 and recent ...

4 months ago - PRNewsWire

Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates

SAN DIEGO , July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along with ...

4 months ago - PRNewsWire

Biotech ETF Tops in June: 5 Stocks That Outperform

Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' barga...

Other symbols: DAWNKZRLYELRPTX
5 months ago - Zacks Investment Research

What's Next For Mirati Therapeutics Stock After A 20% Rise In A Month?

Mirati Therapeutics stock (NASDAQ: MRTX) has risen a solid 20% in a month, outperforming the broader markets with the S&P500 down 6%.

5 months ago - Forbes